Due to the important role of the T cell response in immune checkpoint inhibitor therapy, as well as the recent approval of these drugs for PD-L1-positive CC, it will likely be important to understand the consequences of these differences in antigen presentation capacity on their efficacy in these immunologically distinct cancers. Here, CD274 is linked to cancer.